Cargando…

Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement

OBJECTIVES: There have been few studies that have fully elucidated the relationship between genomic mutations in pulmonary adenocarcinomas and occult lymph node (LN) metastases (pN1-2) despite a preoperative clinical N0 stage (cN0). It is well known that anaplastic lymphoma kinase (ALK) rearrangemen...

Descripción completa

Detalles Bibliográficos
Autores principales: Seto, Katsutoshi, Kuroda, Hiroaki, Yoshida, Tatsuya, Sakata, Shozo, Mizuno, Tetsuya, Sakakura, Noriaki, Hida, Toyoaki, Yatabe, Yasushi, Sakao, Yukinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055903/
https://www.ncbi.nlm.nih.gov/pubmed/30050322
http://dx.doi.org/10.2147/CMAR.S147569
_version_ 1783341273938132992
author Seto, Katsutoshi
Kuroda, Hiroaki
Yoshida, Tatsuya
Sakata, Shozo
Mizuno, Tetsuya
Sakakura, Noriaki
Hida, Toyoaki
Yatabe, Yasushi
Sakao, Yukinori
author_facet Seto, Katsutoshi
Kuroda, Hiroaki
Yoshida, Tatsuya
Sakata, Shozo
Mizuno, Tetsuya
Sakakura, Noriaki
Hida, Toyoaki
Yatabe, Yasushi
Sakao, Yukinori
author_sort Seto, Katsutoshi
collection PubMed
description OBJECTIVES: There have been few studies that have fully elucidated the relationship between genomic mutations in pulmonary adenocarcinomas and occult lymph node (LN) metastases (pN1-2) despite a preoperative clinical N0 stage (cN0). It is well known that anaplastic lymphoma kinase (ALK) rearrangements are more likely to occur in younger patients with high grade tumors. The aim of this study was to investigate the genomic status, examine the clinicopathologic features, and evaluate whether ALK mutations are associated with occult LN metastases. MATERIALS AND METHODS: We retrospectively evaluated 459 Japanese patients who underwent pulmonary resection of cN0 adenocarcinomas between January 2012 and December 2015. The clinicopathologic characteristics, including age, sex, smoking index, tumor maximum diameter and consolidation/tumor ratio on computed tomography (CT), maximum standardized uptake value on positron emission tomography (PET) and gene mutations (epidermal growth factor receptor [EGFR], ALK, and kirsten ras genes (KRAS), were evaluated. RESULTS: ALK and EGFR and KRAS mutations were all mutually exclusive. Among 324 patients found to have mutations, ALK was involved in 19 (5.9%), EGFR in 266 (82.1%), and KRAS in 39 (12.0%). The incidence of occult LN metastases did not differ significantly between those with or without mutations (p=0.27). On univariate and multivariate analyses, tumors with ALK were more likely to have occult LN metastases (p=0.03). In cN0 tumors with ALK, pN1 was diagnosed in 26.3% and pN2 in 10.5%, whereas pN1 or pN2 stage was found in <10.0% in those with EGFR or KRAS mutations or with no mutations at all. No significant difference was found in the 2-year disease-free survival among those with gene mutations (p=0.08). CONCLUSION: This study highlights the frequency of PET- and CT-negative occult LN metastases in resected adenocarcinomas with ALK rearrangement. Our multivariate analysis showed that ALK rearrangements were associated with a significantly higher incidence of occult LN metastasis compared with ALK-negative adenocarcinomas.
format Online
Article
Text
id pubmed-6055903
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60559032018-07-26 Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement Seto, Katsutoshi Kuroda, Hiroaki Yoshida, Tatsuya Sakata, Shozo Mizuno, Tetsuya Sakakura, Noriaki Hida, Toyoaki Yatabe, Yasushi Sakao, Yukinori Cancer Manag Res Original Research OBJECTIVES: There have been few studies that have fully elucidated the relationship between genomic mutations in pulmonary adenocarcinomas and occult lymph node (LN) metastases (pN1-2) despite a preoperative clinical N0 stage (cN0). It is well known that anaplastic lymphoma kinase (ALK) rearrangements are more likely to occur in younger patients with high grade tumors. The aim of this study was to investigate the genomic status, examine the clinicopathologic features, and evaluate whether ALK mutations are associated with occult LN metastases. MATERIALS AND METHODS: We retrospectively evaluated 459 Japanese patients who underwent pulmonary resection of cN0 adenocarcinomas between January 2012 and December 2015. The clinicopathologic characteristics, including age, sex, smoking index, tumor maximum diameter and consolidation/tumor ratio on computed tomography (CT), maximum standardized uptake value on positron emission tomography (PET) and gene mutations (epidermal growth factor receptor [EGFR], ALK, and kirsten ras genes (KRAS), were evaluated. RESULTS: ALK and EGFR and KRAS mutations were all mutually exclusive. Among 324 patients found to have mutations, ALK was involved in 19 (5.9%), EGFR in 266 (82.1%), and KRAS in 39 (12.0%). The incidence of occult LN metastases did not differ significantly between those with or without mutations (p=0.27). On univariate and multivariate analyses, tumors with ALK were more likely to have occult LN metastases (p=0.03). In cN0 tumors with ALK, pN1 was diagnosed in 26.3% and pN2 in 10.5%, whereas pN1 or pN2 stage was found in <10.0% in those with EGFR or KRAS mutations or with no mutations at all. No significant difference was found in the 2-year disease-free survival among those with gene mutations (p=0.08). CONCLUSION: This study highlights the frequency of PET- and CT-negative occult LN metastases in resected adenocarcinomas with ALK rearrangement. Our multivariate analysis showed that ALK rearrangements were associated with a significantly higher incidence of occult LN metastasis compared with ALK-negative adenocarcinomas. Dove Medical Press 2018-07-18 /pmc/articles/PMC6055903/ /pubmed/30050322 http://dx.doi.org/10.2147/CMAR.S147569 Text en © 2018 Seto et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Seto, Katsutoshi
Kuroda, Hiroaki
Yoshida, Tatsuya
Sakata, Shozo
Mizuno, Tetsuya
Sakakura, Noriaki
Hida, Toyoaki
Yatabe, Yasushi
Sakao, Yukinori
Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement
title Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement
title_full Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement
title_fullStr Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement
title_full_unstemmed Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement
title_short Higher frequency of occult lymph node metastasis in clinical N0 pulmonary adenocarcinoma with ALK rearrangement
title_sort higher frequency of occult lymph node metastasis in clinical n0 pulmonary adenocarcinoma with alk rearrangement
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055903/
https://www.ncbi.nlm.nih.gov/pubmed/30050322
http://dx.doi.org/10.2147/CMAR.S147569
work_keys_str_mv AT setokatsutoshi higherfrequencyofoccultlymphnodemetastasisinclinicaln0pulmonaryadenocarcinomawithalkrearrangement
AT kurodahiroaki higherfrequencyofoccultlymphnodemetastasisinclinicaln0pulmonaryadenocarcinomawithalkrearrangement
AT yoshidatatsuya higherfrequencyofoccultlymphnodemetastasisinclinicaln0pulmonaryadenocarcinomawithalkrearrangement
AT sakatashozo higherfrequencyofoccultlymphnodemetastasisinclinicaln0pulmonaryadenocarcinomawithalkrearrangement
AT mizunotetsuya higherfrequencyofoccultlymphnodemetastasisinclinicaln0pulmonaryadenocarcinomawithalkrearrangement
AT sakakuranoriaki higherfrequencyofoccultlymphnodemetastasisinclinicaln0pulmonaryadenocarcinomawithalkrearrangement
AT hidatoyoaki higherfrequencyofoccultlymphnodemetastasisinclinicaln0pulmonaryadenocarcinomawithalkrearrangement
AT yatabeyasushi higherfrequencyofoccultlymphnodemetastasisinclinicaln0pulmonaryadenocarcinomawithalkrearrangement
AT sakaoyukinori higherfrequencyofoccultlymphnodemetastasisinclinicaln0pulmonaryadenocarcinomawithalkrearrangement